Open access
Oct 2026
Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer
This cohort study examines time to next treatment and overall survival associated with initiation of lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) among US patients with metastatic androgen pathway modulator–resistant prostate cancer.
Varun Nandakumar, Y. Jo, M. Ostrowski et al.
· JAMA Network Open · 0 citations